Literature DB >> 2694352

Vibrio vulnificus infection.

Y C Chuang1, C D Young, C W Chen.   

Abstract

We report 3 cases of Vibrio vulnificus infections from Taiwan. Patient 1, who manifested symptoms of primary septicemia, died after 2 days. Patient 2, who had a wound infection and signs and symptoms of sepsis but negative blood cultures, responded to tobramycin and chloramphenicol plus surgical debridement, and recovered after 26 days of hospitalization. Patient 3 had secondary septicemia originating from a wound inflicted by a shrimp. Originally, the patient seemed to respond to ceftazidime and amikacin treatment along with surgical debridement, but subsequently died from adult respiratory distress syndrome (ARDS) induced by several episodes of aspiration which occurred after initial clinical improvements. We conclude that, for patients with severe wounds and evidence of V. vulnificus infection, an appropriate, powerful antibiotic, such as one of the third generation cephalosporins should be used as initial therapy unless the nature of the infection indicates other treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694352     DOI: 10.3109/00365548909021703

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

1.  Cloning and sequence analysis of a novel hemolysin gene (vllY) from Vibrio vulnificus.

Authors:  T M Chang; Y C Chuang; J H Su; M C Chang
Journal:  Appl Environ Microbiol       Date:  1997-10       Impact factor: 4.792

2.  Does Vibrio vulnificus present a health threat to Canadians?

Authors:  S Stavric; B Buchanan
Journal:  Can J Infect Dis       Date:  1997-09

3.  In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.

Authors:  Hung-Jen Tang; Ming-Chung Chang; Wen-Chien Ko; Kun-Yen Huang; Chih-Lung Lee; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.

Authors:  Y C Chuang; J W Liu; W C Ko; K Y Lin; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Infectious complications of cirrhosis.

Authors:  O S Brann
Journal:  Curr Gastroenterol Rep       Date:  2001-08

Review 7.  Vibrio vulnificus in Taiwan.

Authors:  Po-Ren Hsueh; Ching-Yih Lin; Hung-Jen Tang; Hsin-Chun Lee; Jien-Wei Liu; Yung-Ching Liu; Yin-Ching Chuang
Journal:  Emerg Infect Dis       Date:  2004-08       Impact factor: 6.883

8.  pH level as a marker for predicting death among patients with Vibrio vulnificus infection, South Korea, 2000-2011.

Authors:  Na Ra Yun; Dong-Min Kim; Jun Lee; Mi Ah Han
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

9.  Vibrio vulnificus necrotizing fasciitis with sepsis presenting with pain in the lower legs in winter: a case report.

Authors:  Weihua Di; Jing Cui; Hui Yu; Xiao Cui; Huanlan Sa; Zhong Fu; Bingjin Fu; Guofeng Guan; Rui Du; Cuijie Shao; Yong Gao
Journal:  BMC Infect Dis       Date:  2022-08-04       Impact factor: 3.667

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.